Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced that RBD7022 Injection, its independently developed siRNA drug targeting PCSK9, has completed public registration for Phase III clinical trials by collaborator Qilu Pharmaceutical Co., Ltd. The study is about to initiate, advancing the cholesterol‑lowering therapeutic toward potential regulatory approval in Greater China.
Development Milestone
Item
Detail
Licensor
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938)
Licensee/Collaborator
Qilu Pharmaceutical Co., Ltd.
Product
RBD7022 Injection
Drug Class
siRNA (small interfering RNA) targeting PCSK9
Clinical Stage
Phase III registration completed; trial initiation imminent
Territory
Chinese mainland, Hong Kong, Macau (exclusive rights granted to Qilu)
Licensing Date
December 2023
Drug Profile – RBD7022
Feature
Detail
Target
PCSK9 (proprotein convertase subtilisin/kexin type 9)
Mechanism
siRNA‑mediated gene silencing → reduces PCSK9 protein levels
Potential for quarterly or less frequent dosing vs. monoclonal antibody alternatives (Repatha, Praluent)
Strategic Implications
siRNA Cardiovascular Entry: RBD7022 represents Ribo Life Science’s expansion from oncology/rare disease into cardiovascular/metabolic—a larger therapeutic market with significant unmet need for convenient LDL‑lowering options.
Qilu Pharma Execution: The Phase III advancement validates Qilu’s development capabilities and commitment to the 2023 licensing deal, positioning both companies for shared commercial success in Greater China.
PCSK9 Competition: RBD7022 enters a market with approved mAbs (Repatha, Praluent) and oral PCSK9 inhibitors in development; siRNA differentiation lies in dosing frequency and durability.
China Cardiovascular Burden:Hypercholesterolemia affects hundreds of millions in China; effective PCSK9 targeting addresses a major public health priority and reimbursement‑sensitive market.
Market Context
Factor
Impact
PCSK9 Market Size
~ $3‑4 billion globally; growing with cardiovascular outcome data and expanded indications
siRNA vs. mAb Differentiation
Inclisiran (Novartis) approved in EU/US with twice‑yearly dosing; RBD7022 could offer similar convenience advantage
China Market Dynamics
Domestic innovation prioritized; PCSK9 siRNA would be first‑in‑class Chinese‑developed option vs. imported competitors
Qilu Pharma Positioning
Leading Chinese pharma with cardiovascular franchise; RBD7022 complements existing lipid‑lowering portfolio
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase III enrollment, efficacy outcomes, and commercial potential for RBD7022. Actual results may differ due to risks including competitive pricing pressure, manufacturing scale‑up for siRNA production, and reimbursement negotiation challenges in China’s healthcare system.-Fineline Info & Tech
By Fineline Cube